| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Reflex arc (spinal interneurons); central nervous system.
|
|---|---|
| ln Vitro |
Mephenoxalone inhibits neuronal transmission and causes skeletal muscle relaxation by inhibiting reflex arcs. It has muscle relaxant and mild anxiolytic activities. The compound blocks abnormal nerve impulses that cause spasticity. It has neuropharmacologic activity in vivo. Mephenoxalone combines muscle-relaxing and calming effects.
|
| ln Vivo |
Mephenoxalone has neuropharmacologic activity in vivo. It relaxes skeletal muscles by inhibiting the reflex arc. The compound is used clinically to relieve muscle spasms and tension associated with musculoskeletal conditions. It has mild anxiolytic and sedative properties.
|
| Enzyme Assay |
In vitro assays measure the effect of Mephenoxalone on neuronal transmission using spinal cord or brain slice preparations. Electrophysiological recordings (e.g., intracellular or extracellular) are performed to assess the compound's effect on reflex arc activity. Mephenoxalone is applied at concentrations ranging from 1-100 µM. The inhibition of synaptic transmission is quantified. Receptor binding assays can be performed to identify the molecular targets.
|
| Cell Assay |
In vitro cellular assays are performed using neuronal cell lines or primary neuronal cultures. Cells are treated with Mephenoxalone at concentrations ranging from 1-100 µM for 24-72 hours. Neuronal excitability is assessed using calcium imaging or multi-electrode array recordings. Cell viability is monitored using MTT assays. Neurotransmitter release (e.g., GABA, glutamate) can be measured by ELISA or HPLC. Receptor binding and signaling assays are performed to identify molecular targets.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of muscle spasticity (e.g., spinal cord injury models) or anxiety (e.g., elevated plus maze). Mephenoxalone is administered orally or intraperitoneally at doses ranging from 1-50 mg/kg. Muscle tone is assessed using standard scoring systems. Locomotor activity is monitored. Anxiolytic effects are evaluated in behavioral tests. The compound's effects on reflex arc activity can be assessed in spinalized animal preparations.
|
| ADME/Pharmacokinetics |
Mephenoxalone has a molecular weight of 209.24 g/mol and molecular formula C11H15NO3. CAS number: 70-07-5. Store as a powder at room temperature. Soluble in DMSO and organic solvents. For in vivo use, formulate in suitable vehicle for oral or intraperitoneal administration. The compound is stable under normal storage conditions. Purity typically ≥98%.
|
| Toxicity/Toxicokinetics |
Mephenoxalone is generally well-tolerated at therapeutic doses. Side effects may include drowsiness, dizziness, and gastrointestinal disturbances. As a centrally acting muscle relaxant, it may cause sedation and impaired motor coordination. Contraindications include hypersensitivity to the compound and severe hepatic impairment. The compound is for research use only and not for human therapeutic use.
|
| Additional Infomation |
Mephenoxalone belongs to the methoxybenzene class of compounds.
Mephenoxalone is a centrally acting muscle relaxant with mild anxiolytic properties. It is used clinically for the relief of muscle spasms and tension. The compound inhibits neuronal transmission by inhibiting reflex arcs. It is also known as Mephenoxalone. Mephenoxalone is supplied as a research compound with high purity and should be stored at room temperature. It is a valuable tool for studying muscle relaxation and anxiety. |
| Molecular Formula |
C11H13NO3
|
|---|---|
| Molecular Weight |
207.23
|
| Exact Mass |
223.084
|
| CAS # |
70-07-5
|
| PubChem CID |
6257
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
440.0±18.0 °C at 760 mmHg
|
| Flash Point |
219.9±21.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.521
|
| LogP |
1.32
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
16
|
| Complexity |
246
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1OC(COC2=CC=CC=C2OC)CN1
|
| InChi Key |
ZMNSRFNUONFLSP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H13NO4/c1-14-9-4-2-3-5-10(9)15-7-8-6-12-11(13)16-8/h2-5,8H,6-7H2,1H3,(H,12,13)
|
| Chemical Name |
5-[(2-methoxyphenoxy)methyl]-1,3-oxazolidin-2-one
|
| Synonyms |
TAB Lenetranat; Lenetran Lenetran; Mephenoxalone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8256 mL | 24.1278 mL | 48.2556 mL | |
| 5 mM | 0.9651 mL | 4.8256 mL | 9.6511 mL | |
| 10 mM | 0.4826 mL | 2.4128 mL | 4.8256 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
